La catena delle opzioni mostra i dati chiave delle opzioni azionarie di COPT Defense Props a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per COPT Defense Props..

COPT Defense Props (NYSE:CDP) Azioni, Catena delle Opzioni

COPT Defense

COPT Defense Props

COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.

COPT Defense Properties Common Shares of Beneficial Interest

COPT Defense Properties

CANADIAN APT PRP R/E I/T by Canadian Apartment Properties Real Estate Investment Trust

Canadian Apartment Properties Real Estate Investment Trust

News

ZCAR

Zoomcar Partners With CARS24 To Bring Vehicle Inspection And Tracking Standards To Self-Drive Car-Sharing Space

Nokia today announced its latest venture, Enscryb, an energy innovation platform, is partnering with NODES, an energy trading company. In addition, Enscryb has also secured and onboarded two customers: Nanuq, a charging infrastructure company, and Smartecon, a renewable energy provider.

Nokia Announced Enscryb Partnership With NODES For Energy Innovation Platform; Onboards Nanuq And Smartecon As Initial Customers

TLRY

Tilray-Owned Breckenridge Distillery Debuts New Collectors Art Series Bottle Featuring Calvados Cask Finish And Toland Mural

<ul>
<li>Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.</li>
<li>Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH&#xAE; (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025.</li>
<li>Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget.</li>
<li>Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for this multi-billion dollar addressable market.</li>
<li>Company expects to dose first patient in the Phase 3 trial in the United States in the fourth quarter of 2025.</li>
<li>Verrica to maintain ownership of global rights to YCANTH for all indications in all territories outside of Japan</li>
</ul>

Biotech

Health Care

Contracts

General

VRCA

Verrica Pharmaceuticals Announces Second Amendment To Its Existing Collaboration And Licensing Agreement With Torii Pharmaceutical To Initiate A Global Pivotal Phase 3 Trial Of Verrica's Ycanth For Common Warts

Establishes Digital Computing Division to Drive Company's Digital Infrastructure Strategy, Adds Hash Rate of 3.11 EH/s, Expects Significant Bitcoin Mining Revenue, Sets Stage for Future High-Performance Computing (HPC) and AI-driven Entertainment Services Opportunities
ABU DHABI, United Arab Emirates, July 01, 2025 (GLOBE NEWSWIRE) -- NIP Group Inc. ("NIPG" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>), a leading digital entertainment company, today announced it has entered into a definitive asset-purchase agreement (the "Agreement") to acquire on-rack crypto mining machines (the "Products") from Fortune Peak Limited and Apex Cyber Capital Limited (together, the "Sellers"). These Products are currently used for Bitcoin mining and are expected to begin generating significant Bitcoin mining revenue for the Company upon closing of the acquisition. To support this initiative, NIPG has established a dedicated Digital Computing Division to manage the operations of the acquired Products and lead the future development of the Company's compute infrastructure capabilities. Importantly, this transaction marks a strategic extension of NIPG's business into the digital infrastructure space.
The Products, consisting of data center capacity with a combined hash rate of 3.11 EH/s, are currently utilized for Bitcoin mining operations with expected production of approximately 60 Bitcoins per month, and will continue operating immediately after closing of the proposed transaction. Under the terms of the Agreement, NIPG will pay the consideration for the Products through issuance of approximately 119,553,439 Class A ordinary shares of the Company to the Sellers. In connection with the consummation of the proposed transactions contemplated by the Agreement, the Company and the Sellers will also enter into an investor rights agreement to define certain rights and obligations among them with respect to the Company.
The closing of the proposed transaction is expected to occur on or before September 30, 2025, and is subject to customary closing conditions. There can be no assurance that the closing conditions will be satisfied nor that the proposed transaction will be completed before that date or at all.

NIPG

NIP Group Enters Into Definitive Asset-Purchase Agreement To Acquire On-Rack Crypto Mining Machines From Fortune Peak Limited And Apex Cyber Capital Limited

NIVF

NewGen Subsidiary Secures UAE Beachfront Plot; Explores Real World Asset Tokenization Amid $45M Real Estate Push

EDAP TMS SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, announced a change in its U.S. reporting status. EDAP TMS S.A. (the "Company") currently qualifies as a foreign private issuer under applicable U.S. Securities and Exchange Commission ("SEC") rules and regulations. Effective January 1, 2026, the Company will no longer qualify for foreign private issuer status and will begin complying with and reporting under SEC reporting and other rules and Nasdaq listing requirements applicable to U.S. domestic filers, including, but not limited to, requirements with respect to the composition of the Company's board of directors and committees, certain corporate governance matters and shareholder approval of certain actions.

Government

Regulations

EDAP

EDAP TMS Will No Longer Qualify as Foreign Issuer, Adopts US Reporting Rules

Digital Realty Reaches 1.5 GW Of Renewable Energy Capacity Under Contract And Matching 185 Data Centers With 100% Renewable Energy

Management

JBIO

Jade Biosciences Appoints Brad Dahms As Chief Financial Officer

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs,&nbsp;today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy.
Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and industry and has contributed to the successful filing of more than 25 Investigational New Drug (IND) applications. He joins Avacta from Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>), where he served as Senior Vice President of early-stage clinical development, overseeing the clinical strategy for DNA-based vaccines and immunotherapies. Prior to that, he held senior roles at Xencor, Vaxart, and Amgen, with a consistent focus on oncology, immunotherapy, and translational science. At Vaxart, Dr. Liebowitz led the acquisition and execution of a significant BARDA contract as principal investigator, culminating in successful completion of the award. Earlier in his career, he held key R&amp;D leadership roles at Amgen, where he directed oncology and vascular biology drug discovery at the company's Washington research site.
 &nbsp;

Avacta Appoints Dr. David Liebowitz as Chief Medical Officer to Lead Cancer Drug Strategy

INVX

Innovex Completes All-Cash Divestment Of Subsea Tree Product Line To Trendsetter Engineering

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Buy and maintains $44 price target.

Price Target

Reiteration

Analyst Ratings

SMMT

HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target

BTAI

BioXcel Therapeutics Announced The Second Positive Recommendation By An Independent Data Safety Monitoring Board To Continue, Without Modification, SERENITY At-home Pivotal Phase 3 Safety Trial Of BXCL501 For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia

<a href="https://www.globenewswire.com/Tracker?data=B7tw_SO0EIaKsJ8U2ptgerj7MQYCVzKu9NFy1vl5dbf25_WFwPTEk9FUz6pFUgrxvl9l8LMTwVdxsDfKbDsPBxe-e-QJ8GEz1U8K3jJGCbs=">Banzai International, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) ("Banzai" or the "Company"), a leading marketing technology company that provides essential marketing and sales solutions, today announced the completion of an $11.0 million dollar debt facility with an institutional investor to support acquisitions and ongoing operations.
The financing includes an initial tranche of $2.2 million (the "Note"), which matures on June 30, 2026, bears interest at 10% per annum, and is secured by the Company's assets. The principal amount of the Note is payable in cash or convertible in whole or in part into common shares at the holder's discretion at 115% of the price of the common stock immediately preceding the Closing Date. The company has the right to draw subsequent tranches, provided that certain conditions are met or waived.
Banzai intends to use the net proceeds from the facility for working capital, acquisitions, and general corporate purposes to support its future growth.

BNZI

Banzai Secures $11M Debt Deal to Fuel Acquisitions and Growth Plans

KIRK

Kirkland's Appoints Andrea Courtois As SVP, CFO, Succeeding Mike Madden, Effective July 21, 2025

Steel Dynamics, Inc. (NASDAQ/GS: STLD) today announced each of the company's steel mills achieved Global Steel Climate Council (GSCC) product certification. The GSCC provides product certification, validating that these steel products are on the glidepath to achieve the goals of the Paris Climate Agreement's 1.5° C scenario.
&nbsp;
The GSCC's Steel Climate Standard provides a single, technology neutral framework for product certification allowing steel customers transparency when making lower-carbon emissions steel product purchasing decisions. The Steel Climate Standard is aligned with the International Energy Agency's Net Zero by 2050: A Roadmap for the Global Energy Sector. The Steel Climate Standard measures key steelmaking greenhouse gas (GHG) emissions through hot rolling including Scope 1, Scope 2, and upstream Scope 3 emissions categories. Each of the company's steel mills 2024 GHG emissions intensity data were verified by a third-party, KERAMIDA, and certified by the GSCC.

STLD

Steel Dynamics Earns Global Climate Certification for All Mills, Advancing Low-Carbon Steel Goals

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy rating and announces Price Target of $30.

Initiation

TVTX

HC Wainwright & Co. Assumes Travere Therapeutics at Buy, Announces Price Target of $30

Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) today announced that it has entered into a definitive agreement to purchase the containerboard business of Greif, Inc. for $1.8 billion in cash. The transaction is expected to close by the end of PCA's third quarter, subject to certain customary conditions and regulatory approvals.
The Greif containerboard business includes two containerboard mills with approximately 800,000 tons of production capacity and eight sheet feeder and corrugated plants located across the United States. The business generated approximately $1.2 billion in sales and $212 million of earnings before interest, taxes, depreciation and amortization (EBITDA) for the 12 months ended April 30, 2025 (the LTM period).
Synergies are estimated to generate pre-tax benefits of approximately $60 million and are expected to be fully realized within two years after closing. The synergies are projected to come from improved operational and production capabilities and efficiencies at the mills, increased integration, mill grade optimization and lower transportation costs. Approximately one half of the benefits are expected by the end of the first year with the remainder being received by the end of the second year.
The purchase price represents a multiple of 8.5X LTM EBITDA and, with $60 million in benefits from synergies, the purchase price represents a multiple of 6.6X LTM EBITDA. The acquisition is expected to be accretive to earnings immediately.
PCA is expected to finance the transaction with $1.5 billion of new debt and cash on hand. PCA's pro forma leverage ratio (net debt to EBITDA) will be approximately 1.7X after completion of the transaction.

Packaging Corporation Of America Agrees To Purchase Containerboard Business Of Greif For $1.8B In Cash

The GEO Group, Inc. (NYSE:<a href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) ("GEO" or the "Company") announced today that it has entered into a purchase agreement with SDCC Middle Block, LLC (the "Seller"), an affiliate of Holland Partners Group, to acquire the 770-bed Western Region Detention Facility located in San Diego, California (the "San Diego Facility") for $60 million. GEO currently leases the San Diego Facility for approximately $5.1 million annually under a lease agreement that expires on March 31, 2029. GEO has a contract with the U.S. Marshals Service for the exclusive use of the San Diego Facility, which generates approximately $57 million in annualized revenues.
The purchase of the San Diego Facility is expected to close on July 31, 2025, subject to the satisfaction of customary closing conditions, and is expected to be funded as a like kind real estate property exchange with proceeds from the previously announced sale of the GEO-owned Lawton Correctional Facility in Oklahoma (the "Lawton Facility"), which is expected to close on July 25, 2025, resulting in an estimated capital gains cash tax savings of approximately $9.5 million.
Following the closing of the sale of the Lawton Facility and the purchase of the San Diego Facility, GEO expects to have approximately $222 million in net proceeds. GEO expects to use the net proceeds, along with cash on hand and available liquidity, to pay off senior secured debt, including approximately $300 million in floating rate debt, which is expected to position GEO to consider potential future capital returns.

GEO Group Enters Into Purchase Agreement With SDCC Middle Block To Acquire 770-Bed Western Region Detention Facility In San Diego, California For $60M

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) with a Buy and maintains $13 price target.

PDSB

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $13 Price Target

Press Releases

COPT Defense Reports Strong Full Year 2024 Results

COPT Defense Establishes 2025 Guidance

COPT Defense Increases Quarterly Dividend by 3.4%

COPT Defense to Present at Citi's 2025 Global Property CEO Conference

COPT Defense Executes 48,000 SF Lease with a Top 10 U.S. Defense Contractor at Franklin Center in Columbia Gateway

COPT Defense Provides Conference Call Details to Discuss 1Q 2025 Results

COPT Defense Executes Two Investment Leases in Redstone Gateway Totaling 55,000 SF, Bringing Total Portfolio Year-to-Date Investment Leasing to 103,000 SF

Comments

COPT Defense Props

COPT Defense Props (CDP) Opzioni

COPT Defense Props (NYSE:CDP) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO